Non-exudative Age-related Macular Degeneration Clinical Trial
Official title:
A Prospective Study Examining Patients With Non-exudative Age-related Macular Degeneration (NEAMD) of Different Severity
Age-related macular degeneration (AMD) is the most prevalent cause of vision loss in
developed countries and is often discussed in terms of the "dry" and the "wet" forms. The
"wet" form of AMD is the more advanced form of the disease and is responsible for 80% of the
legal blindness in AMD. Treatment options include a promising class of biologics called
anti-vascular endothelial growth factors, as well as photodynamic therapy and laser surgery.
These therapies can slow further vision loss, but cannot achieve recovery of lost vision. The
"wet" form of AMD is always preceded by the "dry" form. Therefore, it is reasonable to expect
that the early detection and treatment of the "dry" form may help reduce vision loss or
progression to the more damaging "wet" form. Unfortunately, symptoms appear only in advanced
stages of the "dry" form. As light sensitive cells in the macula breakdown in a process
called geographic atrophy, the patient may notice blurred central vision.
OCT is an imaging technology that can perform non-contact cross-sectional imaging of retinal
and choroidal tissue structure in real time. It is analogous to ultrasound B-mode imaging,
except that OCT measures the intensity of reflected light rather than acoustical waves.
This study aims is to use OCT technology to compare how the retinal anatomy and blood flow
differ within three severity groupings of non-exudative age-related macular degeneration
(NEAMD).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01736059 -
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
|
Phase 1 |